Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
4
Neutral
2
Bullish
8
Bearish
32
Neutral
6
Bullish
8
Bearish
28
Neutral
4
Bullish
0
Discovery themes featuring this stock
Bal Pharma is a leading Indian pharmaceutical company engaged in the production and distribution of prescription drugs, branded formulations, APIs, and OTC products. Their operations extend throughout India with a well-established distribution network.
The company specializes in diverse therapeutic areas, including anti-infectives, pain management, respiratory care, and women's health, showcasing a wide range of products under various prominent brands.
Bal Pharma integrates modern and herbal medicines through its Bal Vedics division, targeting specific health conditions like prostate enlargement, renal calculi, and infertility.
The company has a strong institutional presence, collaborating with top government bodies and hospitals to extend product reach to the masses.
Bal Pharma's infrastructure includes three units dedicated to manufacturing various forms of pharmaceuticals, supported by substantial R&D and quality control facilities.
Pharmaceuticals & Biotechnology
Pharmaceuticals
70 Cr
Low Risk
52.0
34.1
0.1
2.8
61.80
26.69
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
47.75 | 73 Cr | 37.73 | 2.57 | 0.00 | 6.80 | 10.18 | 5.52 | ||
16.82 | 73 Cr | -4.02 | 0.00 | 0.00 | -22.95 | -11.16 | -9.61 | ||
40.00 | 73 Cr | -345.38 | 1.31 | 0.00 | -0.39 | 1.12 | -0.22 | ||
48.65 | 70 Cr | 51.97 | 2.76 | 0.00 | 6.27 | 3.99 | 4.89 | ||
34.89 | 67 Cr | -6.60 | 1.52 | 0.00 | -117.41 | -22.41 | -11.20 | ||
104.50 | 67 Cr | 19.75 | 2.60 | 0.00 | 13.20 | 16.60 | 8.28 | ||
3.80 | 65 Cr | 15.19 | 0.72 | 0.00 | 4.74 | 5.92 | 3.58 | ||
| Median: 7 Co. | — | 40.00 | 70 Cr | 15.19 | 1.52 | 0.00 | 4.74 | 3.99 | 3.58 |
Bacil Pharma Ltd (BACPHAR) is currently trading at 43.67 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bal Pharma is a leading Indian pharmaceutical company engaged in the production and distribution of prescription drugs, branded formulations, APIs, and OTC products. Their operations extend throughout India with a well-established distribution network. The company specializes in diverse therapeutic areas, including anti-infectives, pain management, respiratory care, and women's health, showcasing a wide range of products under various prominent brands. Bal Pharma integrates modern and herbal medicines through its Bal Vedics division, targeting specific health conditions like prostate enlargement, renal calculi, and infertility. The company has a strong institutional presence, collaborating with top government bodies and hospitals to extend product reach to the masses. Bal Pharma's infrastructure includes three units dedicated to manufacturing various forms of pharmaceuticals, supported by substantial R&D and quality control facilities.
Over the past 52 weeks, Bacil Pharma Ltd has traded between a low of ₹26.69 and a high of ₹61.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bacil Pharma Ltd has a market capitalization of approximately 69.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bacil Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.97 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 69.64 Cr, Bacil Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bacil Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bacil Pharma Ltd is 51.97. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
